Literature DB >> 2787832

Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

L Bergui1, M Schena, G Gaidano, M Riva, F Caligaris-Cappio.   

Abstract

PBMC from 11 patients with multiple myeloma (MM) were cultured in vitro in presence of IL-3 and IL-6. After 3 d, actively proliferating immunoblast-like B cells (20-62%) were apparent. After 6 d, a population of morphologically evident plasma cells was observed (30-50%) that expressed, in each individual case, the same light and heavy chain produced by bone marrow malignant plasma cells. We conclude that in MM the malignant plasma cell precursors are circulating and their growth and terminal differentiation are under the synergistic control of IL-3 and IL-6.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787832      PMCID: PMC2189411          DOI: 10.1084/jem.170.2.613

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

Review 1.  Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation.

Authors:  R G Lynch; J W Rohrer; B Odermatt; H M Gebel; J R Autry; R G Hoover
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  B-cell neoplasia in man.

Authors:  S E Salmon; M Seligmann
Journal:  Lancet       Date:  1974-11-23       Impact factor: 79.321

3.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells.

Authors:  F Malavasi; F Caligaris-Cappio; C Milanese; P Dellabona; P Richiardi; A O Carbonara
Journal:  Hum Immunol       Date:  1984-01       Impact factor: 2.850

5.  Monoclonal lymphocyte population in human plasma cell myeloma.

Authors:  H Mellstedt; S Hammarström; G Holm
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

6.  Multiple myeloma: circulating lymphocytes that express plasma cell antigens.

Authors:  G J Ruiz-Argüelles; J A Katzmann; P R Greipp; N J Gonchoroff; J P Garton; R A Kyle
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

7.  Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

Authors:  F Caligaris-Cappio; L Bergui; L Tesio; G Pizzolo; F Malavasi; M Chilosi; D Campana; B van Camp; G Janossy
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

8.  CALLA-positive myeloma: an aggressive subtype with poor survival.

Authors:  B G Durie; T M Grogan
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

9.  Interleukin-3 supports growth of mouse pre-B-cell clones in vitro.

Authors:  R Palacios; G Henson; M Steinmetz; J P McKearn
Journal:  Nature       Date:  1984 May 10-16       Impact factor: 49.962

10.  Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.

Authors:  H Kubagawa; L B Vogler; J D Capra; M E Conrad; A R Lawton; M D Cooper
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  24 in total

1.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 3.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

4.  Secretory IgA in saliva can be a useful stress marker.

Authors:  S Tsujita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1999-04       Impact factor: 3.674

5.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

6.  Phenotype and immunoglobulin gene configuration of blood B cells from patients with multiple myeloma.

Authors:  Y Levy; C Schmitt; A Tsapis; J C Brouet; J P Fermand
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

7.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 8.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

Review 9.  Cancer stem cells: controversies in multiple myeloma.

Authors:  Sarah K Brennan; William Matsui
Journal:  J Mol Med (Berl)       Date:  2009-09-17       Impact factor: 4.599

10.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.